(S,R,S)-AHPC-PEG3-propionic acid

 CAS No.: 2140807-42-5  Cat No.: BP-100129  Purity: ≥95% by HPLC 4.5  

(S,R,S)-AHPC-PEG3-propionic acid is a highly specialized E3 Ligase Ligand-Linker Conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) research and drug discovery. This compound features the well-characterized (S,R,S)-AHPC moiety, which selectively binds to the Von Hippel-Lindau (VHL) E3 ubiquitin ligase, linked via a polyethylene glycol (PEG3) spacer to a propionic acid functional group. The PEG3 linker provides optimal flexibility and solubility for constructing bifunctional molecules. As a key intermediate in the synthesis of PROTAC molecules, (S,R,S)-AHPC-PEG3-propionic acid enables the targeted degradation of disease-related proteins by recruiting the VHL E3 ligase to a specific target protein. This results in the ubiquitination and subsequent proteasomal degradation of the target, offering a powerful approach for therapeutic intervention, particularly in cancer and neurodegenerative disease research. With its robust design, this conjugate streamlines the development of next-generation PROTACs and other protein degraders, supporting both academic and pharmaceutical research into selective protein knockdown strategies.

(S,R,S)-AHPC-PEG3-propionic acid

Structure of 2140807-42-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C₃₂H₄₆N₄O₉S
Molecular Weight
662.79

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
≥95% by HPLC
Storage
Store at -20°C
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
3-[2-[2-[3-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]propanoic acid
Synonyms
VH 032 - linker 4
InChI Key
YHEJFYORSLEJKX-BEYSDYMESA-N
InChI
1S/C32H46N4O9S/c1-21-28(46-20-34-21)23-7-5-22(6-8-23)18-33-30(41)25-17-24(37)19-36(25)31(42)29(32(2,3)4)35-26(38)9-11-43-13-15-45-16-14-44-12-10-27(39)40/h5-8,20,24-25,29,37H,9-19H2,1-4H3,(H,33,41)(H,35,38)(H,39,40)/t24-,25+,29-/m1/s1
Canonical SMILES
CC1=C(C2=CC=C(C=C2)CNC([C@@H]3C[C@H](CN3C([C@H](C(C)(C)C)NC(CCOCCOCCOCCC(O)=O)=O)=O)O)=O)SC=N1
Pub Chem ID
132020301

Background Introduction

(S,R,S)-AHPC-PEG3-propionic acid is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation approaches, particularly in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). The AHPC moiety is a thalidomide derivative recognized for efficiently recruiting the von Hippel-Lindau (VHL) E3 ubiquitin ligase, while the PEG3-propionic acid linker enhances solubility and flexibility for conjugation with diverse target-binding ligands.

Mechanism

This molecule functions as a critical component in PROTAC strategy by utilizing the AHPC moiety to bind VHL E3 ligase. The PEG3-propionic acid linker provides structural flexibility and optimal spatial arrangement, improving the formation and stability of the ternary complex between the E3 ligase and the target protein. Through conjugation of (S,R,S)-AHPC-PEG3-propionic acid to a ligand specific for a protein of interest, the resulting PROTAC molecule brings the target protein into close proximity with the E3 ligase. This proximity induces ubiquitination of the target protein, leading to its recognition and degradation by the cellular proteasome system.

Applications

(S,R,S)-AHPC-PEG3-propionic acid is widely utilized in medicinal chemistry and chemical biology for the rational design of VHL-recruiting PROTACs. Applications include the synthesis of bifunctional molecules for targeted degradation of challenging proteins, proof-of-concept studies in drug discovery, and validation of novel drug targets. Its superior solubility and functional handle enable flexible conjugation, making it ideal for research in oncology, immunology, neurodegeneration, and other therapeutic areas where selective protein degradation is desired.

• PEG3 linker ensures excellent solubility and flexible molecular design for PROTAC development.
• Selective VHL E3 ligase binder maximizes targeted protein degradation efficiency.
1. Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?
Anandita Pal, Adam H Metherel, Lauren Fiabane, Nicole Buddenbaum, Richard P Bazinet, Saame Raza Shaikh Nutrients. 2020 Dec 2;12(12):3718.doi: 10.3390/nu12123718.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are n-3 polyunsaturated fatty acids (PUFAs) consumed in low abundance in the Western diet. Increased consumption of n-3 PUFAs may have beneficial effects for a wide range of physiological outcomes including chronic inflammation. However, considerable mechanistic gaps in knowledge exist about EPA versus DHA, which are often studied as a mixture. We suggest the novel hypothesis that EPA and DHA may compete against each other through overlapping mechanisms. First, EPA and DHA may compete for residency in membrane phospholipids and thereby differentially displace n-6 PUFAs, which are highly prevalent in the Western diet. This would influence biosynthesis of downstream metabolites of inflammation initiation and resolution. Second, EPA and DHA exert different effects on plasma membrane biophysical structure, creating an additional layer of competition between the fatty acids in controlling signaling. Third, DHA regulates membrane EPA levels by lowering its rate of conversion to EPA's elongation product n-3 docosapentaenoic acid. Collectively, we propose the critical need to investigate molecular competition between EPA and DHA in health and disease, which would ultimately impact dietary recommendations and precision nutrition trials.
2. Evaluation of an ex vivo model implication for carrier-mediated retinal drug delivery
Viral Kansara, Ashim K Mitra Curr Eye Res. 2006 May;31(5):415-26.doi: 10.1080/02713680600646890.
Purpose:The purpose of this study was to evaluate the implication of an ex vivo model for carrier-mediated retinal drug delivery using an Ussing chamber system. Methods:Dutch Belted Pigmented rabbits weighing 2-2.5 kg were used in these studies. Excised posterior segment tissues (RPE-choroid-sclera and sclera), mounted on the Ussing chamber, were used as an ex vivo model. Transport studies were carried out across sclera and RPE-choroid-sclera (RCS) tissue preparations in the sclera to retina (S --> R) and retina to sclera (R --> S) directions for 3 hr at 37 degrees C. The model was validated by permeability studies with paracellular and transcellular markers ([(3)H]mannitol and [(14)C]diazepam, respectively), tissue viability studies (bioelectrical and biochemical assays), and tissue histology and electron microscopy studies. Functional presence of a carrier-mediated transport system for folic acid (folate receptor alpha) was investigated on the basolateral side of the rabbit retina. Results:Results from bioelectrical, biochemical, and histological evaluation of tissue provide evidence that the RCS tissue preparation remains viable during the period of transport study. Permeability values of [(3)H]mannitol across sclera were 4.18 +/- 1.09 x 10(- 5) cm/s (R --> S) and 4.11 +/- 1.09 x 10(- 5) cm/s (S --> R) and across RCS were 1.77 +/- 0.31 x 10(- 5) cm/s (S --> R) and 1.60 +/- 0.19 x 10(- 5) cm/s (R --> S). Permeability values of [(14)C]diazepam across sclera were 2.37 +/- 0.38 x 10(- 5) cm/s (R --> S) and 2.70 +/- 0.70 x 10(- 5) cm/s (S --> R) and across RCS were 3.12 +/- 0.12 x 10(- 5) cm/s (R --> S) and 2.77 +/- 0.25 x 10(- 5)cm/s (S --> R). The rate of [(3)H]folic acid transport across RCS was found to be significantly higher in the S -->R direction (16.34 +/- 0.94 fmoles min(-1) cm(-2)) as compared with R --> S direction (9.38 +/- 1.44 fmoles min(-1) cm(-2)) and nearly 10-fold higher across sclera as compared with RCS in both directions. Transport of [(3)H]folic acid was found to be pH and temperature dependent and was inhibited by 44.5%, 35.1%, and 50.3% in the presence of unlabeled folic acid, 5-methyltetrahydrofolate (MTF), and Methotrexate (MTX).Conclusions:The RCS tissue preparation mounted on the Ussing chamber system, an ex vivo model, can be a useful tool for identification and characterization of carrier-mediated systems present on RPE (a major barrier for retinal drug delivery) and to study carrier-mediated retinal drug delivery via prodrug derivatization.
3. Remediation of Smelter Contaminated Soil by Sequential Washing Using Biosurfactants
Zygmunt Mariusz Gusiatin, Jurate Kumpiene, Ivan Carabante, Maja Radziemska, Martin Brtnicky Int J Environ Res Public Health. 2021 Dec 7;18(24):12875.doi: 10.3390/ijerph182412875.
This paper presents experimental results from the use of biosurfactants in the remediation of a soil from a smelter in Poland. In the soil, concentrations of Cu (1659.1 mg/kg) and Pb (290.8 mg/kg) exceeded the limit values. Triple batch washing was tested as a soil treatment. Three main variants were used, each starting with a different plant-derived (saponin, S; tannic acid, T) or microbial (rhamnolipids, R) biosurfactant solution in the first washing, followed by 9 different sequences using combinations of the tested biosurfactants (27 in total). The efficiency of the washing was determined based on the concentration of metal removed after each washing (CR), the cumulative removal efficiency (Ecumulative) and metal stability (calculated as the reduced partition index, Ir, based on the metal fractions from BCR sequential extraction). The type of biosurfactant sequence influenced the CR values. The variants that began with S and R had the highest average Ecumulative for Cu and Pb, respectively. The Ecumulative value correlated very strongly (r > 0.8) with the stability of the residual metals in the soil. The average Ecumulative and stability of Cu were the highest, 87.4% and 0.40, respectively, with the S-S-S, S-S-T, S-S-R and S-R-T sequences. Lead removal and stability were the highest, 64-73% and 0.36-0.41, respectively, with the R-R-R, R-R-S, R-S-R and R-S-S sequences. Although the loss of biosurfactants was below 10% after each washing, sequential washing with biosurfactants enriched the soil with external organic carbon by an average of 27-fold (S-first variant), 24-fold (R first) or 19-fold (T first). With regard to environmental limit values, metal stability and organic carbon resources, sequential washing with different biosurfactants is a beneficial strategy for the remediation of smelter-contaminated soil with given properties.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g
Historical Records:

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket